8-K: Waters Corp Beats Q2, Raises Full-Year Outlook

Waters Corporation reported strong second-quarter 2025 financial results, exceeding sales and EPS guidance, and raised its full-year outlook.

Summary

• Sales for the second quarter of 2025 were $771 million, an increase of 9% as reported and 8% in constant currency, compared to $709 million in Q2 2024.
• GAAP diluted earnings per share (EPS) for Q2 2025 was $2.47, up from $2.40 in Q2 2024.
• Non-GAAP EPS for Q2 2025 grew 12% to $2.95, compared to $2.63 in Q2 2024.
• Instrument sales grew mid-single-digits in constant currency, with high-single-digit LC and MS growth.
• Recurring revenue increased 11% in constant currency, driven by 9% service growth and double-digit chemistry growth.
• Pharmaceutical market sales grew 11% in constant currency, and Industrial market sales grew 6% in constant currency.
• Academic & Government market sales declined 3% in constant currency, performing better than expected.
• Full-year 2025 constant currency sales growth guidance was raised to +5.5% to +7.5%.
• Full-year 2025 non-GAAP EPS guidance was raised to $12.95 to $13.05, reflecting approximately +9% to +10% year-over-year growth.
• Third-quarter 2025 constant currency sales growth is expected in the range of +5.0% to +7.0%.
• Third-quarter 2025 non-GAAP EPS is expected to be in the range of $3.15 to $3.25.
• Net cash provided by operating activities for the six months ended June 28, 2025, was $300.7 million.
• Free cash flow for the six months ended June 28, 2025, was $392.5 million.

Sentiment

Score: 9

Explanation: The company reported strong financial results exceeding guidance, raised its full-year outlook, and announced a significant strategic transaction (combination with BD Biosciences & Diagnostic Solutions) expected to drive future growth and value creation. Management commentary is highly positive regarding execution and future prospects.

Positives

• Sales of $771 million exceeded guidance range for Q2 2025.
• Non-GAAP EPS of $2.95 was above the mid-point of guidance range for Q2 2025.
• Strong instrument replacement trends, particularly among large pharma and CDMO customers, drove performance.
• Robust growth in recurring revenue (service and chemistry) at 11% constant currency.
• Significant growth in the Pharmaceutical (11% constant currency) and Industrial (6% constant currency) markets.
• Academic & Government segment performed better than expected despite a decline.
• Full-year 2025 constant currency sales growth guidance was raised to +5.5% to +7.5%.
• Full-year 2025 non-GAAP EPS guidance was raised to $12.95 to $13.05.
• The proposed combination with BD Biosciences & Diagnostic Solutions is expected to accelerate strategy into high-growth adjacencies and drive substantial value creation for shareholders through synergies.
• Net debt decreased from $1,626.5 million at December 31, 2024, to $1,457.0 million at June 28, 2025.

Negatives

• Academic & Government sales declined 3% in constant currency for Q2 2025.
• TA operating segment sales declined 6% in constant currency for Q2 2025.
• Net cash provided by operating activities for Q2 2025 decreased to $41.1 million from $54.5 million in Q2 2024.

Risks

• One or more closing conditions to the proposed transaction with BD and SpinCo, including certain regulatory approvals, may not be satisfied or waived on a timely basis or at all.
• A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations, or restrictions.
• The required approval by Waters stockholders for the proposed transaction may not be obtained.
• The proposed transaction may not be completed on the terms or in the timeframe expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the transaction or integrating the businesses, may occur.
• Difficulties and delays in the combined company achieving revenue and cost synergies are possible.
• Inability of the combined company to retain and hire key personnel could impact operations.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations in connection with the proposed transaction may affect timing or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the company.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs could affect results.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the pendency of the proposed transaction on relationships with employees, customers, suppliers, or other counterparties.

Future Outlook

Waters Corporation is raising its full-year 2025 constant currency sales growth guidance to +5.5% to +7.5% and its non-GAAP EPS guidance to $12.95 to $13.05. For the third quarter of 2025, the company expects constant currency sales growth of +5.0% to +7.0% and non-GAAP EPS in the range of $3.15 to $3.25. The proposed combination with BD Biosciences & Diagnostic Solutions is anticipated to accelerate the company's strategy into high-growth adjacencies and drive substantial value creation for shareholders through synergies.

Management Comments

• "Our team continues to execute extremely well and we delivered excellent results again this quarter, driven by robust instrument replacement trends—particularly among large pharma and CDMO customers."
• "Our performance reflects strong execution against our commercial growth initiatives, rapid uptake of our new products, and contribution from incremental growth vectors such as GLP-1s, PFAS and generics."
• "The strength of our core business provides the foundation for our next phase of growth. Our combination with BD Biosciences & Diagnostic Solutions accelerates our strategy into multiple high-growth adjacencies, while extending the reach of our proven execution model into resilient, high-volume end markets."
• "We are well positioned to drive substantial value creation for shareholders with synergies that create immediate impact."
• "Integration planning is underway, and I’m pleased to share that Chris Ross, SVP of Global Operations, will lead this effort. Chris and I successfully partnered on the EMD MilliporeSigma-Aldrich integration, and I’m confident in his leadership to deliver strong results once again."

Industry Context

Waters Corporation's strong performance, particularly in instrument replacement and recurring revenue, indicates robust demand within the life sciences sector, especially from large pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs). The company's focus on growth vectors like GLP-1s, PFAS, and generics aligns with current high-growth and regulatory-driven areas in the pharmaceutical and environmental industries. The proposed combination with BD Biosciences & Diagnostic Solutions signifies a strategic move to expand into high-growth adjacencies and resilient, high-volume end markets, positioning Waters to diversify its offerings and strengthen its competitive standing in the broader analytical instruments and diagnostics landscape.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, and potential for significant value creation from the strategic combination with BD Biosciences & Diagnostic Solutions.
• Employees: Integration planning for the BD Biosciences & Diagnostic Solutions combination is underway, potentially impacting roles and responsibilities, with a retention bonus obligation from the Wyatt acquisition noted.
• Customers: Continued strength in instrument replacement and rapid uptake of new products suggest ongoing strong customer relationships and product relevance, particularly for large pharma and CDMOs.
• Suppliers: No direct impact mentioned, but overall strong company performance generally indicates stable demand for inputs.

Next Steps

• Waters Corporation will webcast its second quarter 2025 financial results conference call on August 4, 2025.
• Integration planning for the combination with BD Biosciences & Diagnostic Solutions is underway, led by Chris Ross, SVP of Global Operations.
• Waters, Augusta SpinCo Corporation, and Becton, Dickinson and Company intend to file relevant materials with the SEC, including a registration statement on Form S-4 by Waters and a registration statement on Form 10 by SpinCo, in connection with the proposed transaction.
• A definitive proxy statement/prospectus of Waters will be mailed to stockholders of Waters.

Key Dates

Recommendation

The company delivered exceptional Q2 2025 results, surpassing both sales and EPS guidance, and significantly raised its full-year outlook. This demonstrates strong operational execution and market demand. Furthermore, the strategic combination with BD Biosciences & Diagnostic Solutions is a transformative move, expected to accelerate growth into high-potential adjacencies and generate substantial synergies. The management team has a proven track record of successful integrations, instilling confidence in the execution of this new venture. The robust core business performance combined with a clear, accretive growth strategy makes Waters Corporation a compelling investment.

Keywords

Waters Corporation, WAT, Financial Results, Q2 2025, Earnings, Guidance, Analytical Instruments, Separations Technologies, Mass Spectrometry, Liquid Chromatography, Life Sciences, Pharmaceutical, Industrial, Recurring Revenue, Becton Dickinson, BD, Spin-off, Acquisition, Corporate Strategy, GLP-1s, PFAS, Generics